Rhythm Pharmaceuticals, Inc.
RM-718
hypothalamic obesity
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for RM-718 in hypothalamic obesity are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“Ongoing Ph2 trial with RM-718”